0001572426-16-000189.txt : 20160701 0001572426-16-000189.hdr.sgml : 20160701 20160701195826 ACCESSION NUMBER: 0001572426-16-000189 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160701 FILED AS OF DATE: 20160701 DATE AS OF CHANGE: 20160701 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nexvet Biopharma plc CENTRAL INDEX KEY: 0001618561 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK STREET 2: RAHAN ROAD CITY: TULLAMORE , CO. OFFALY STATE: L2 ZIP: R35 FR98 BUSINESS PHONE: 353 1 215 8100 MAIL ADDRESS: STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK STREET 2: RAHAN ROAD CITY: TULLAMORE , CO. OFFALY STATE: L2 ZIP: R35 FR98 FORMER COMPANY: FORMER CONFORMED NAME: NEXVET BIOPHARMA Ltd DATE OF NAME CHANGE: 20140903 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Farrell Geraldine T CENTRAL INDEX KEY: 0001632385 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36828 FILM NUMBER: 161747881 MAIL ADDRESS: STREET 1: C/O NEXVET BIOPHARMA PLC STREET 2: NATL INST, FOSTERS AVENUE, MOUNT MERRION CITY: BLACKROCK STATE: L2 ZIP: 00000 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2016-07-01 0001618561 Nexvet Biopharma plc NVET 0001632385 Farrell Geraldine T C/O NEXVET BIOPHARMA PLC UNIT 5, SRAGH TECHNOLOGY PARK, RAHAN RD TULLAMORE L2 R35 FR98 IRELAND 0 1 0 0 VP Operations, General Counsel Ordinary Shares 2016-07-01 4 M 0 2867.00 .125 A 24120.00 I By Geraldine Therese Farrell & Andrew John Benston <Bulla Bulla Famil A/C> Ordinary Shares 2016-07-01 4 M 0 2340.00 .125 A 6640 D Options to Purchase Shares .125 2016-07-01 4 M 0 2867.00 0.00 D 2019-07-01 Ordinary Shares 2867.00 2866.00 I By Geraldine Therese Farrell & Andrew John Benston <Bulla Bulla Family A/C> Restricted Share Units .125 2016-07-01 4 M 0 2340.00 0.00 D 2020-07-01 Ordinary Shares 2340.00 7018.00 D The reporting person and her spouse have shared voting and dispositive power with respect to these reported securities. The remaining 2,866 options will vest and become exercisable on 7/1/17. 2,340 of the Restricted Share Units shall vest and become convertible on 7/1/17 and 2,339 of the Restricted Share Units shall vest and become convertible on each of 7/1/18 and 7/1/19, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting. /s/ Geraldine T. Farrell 2016-07-01